Evidence map›Paper›PMID 41728831›Full record

ArticleJournal of psychopharmacology (Oxford, England)2026

Antipsychotic co-medication and treatment response to rTMS and iTBS in depression: Data from clinical records from two independent clinical sites.

Amelie Völkel, Joshua Tritsch, Marco Poli, Katharina Kerkel, Alkomiet Hasan, Berthold Langguth, Andreas Reissmann, Wolfgang Strube

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amelie VölkelFaculty of Medicine, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Augsburg, Bavaria, Germany.ORCID 0009-0008-1682-5070
Joshua TritschFaculty of Medicine, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Augsburg, Bavaria, Germany.ORCID 0009-0001-7110-5956
Marco PoliFaculty of Medicine, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Augsburg, Bavaria, Germany.ORCID 0009-0000-9092-815X
Katharina KerkelDepartment of Psychiatry and Psychotherapy, University of Regensburg, Germany.
Alkomiet HasanFaculty of Medicine, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Augsburg, Bavaria, Germany.
Berthold LangguthDepartment of Psychiatry and Psychotherapy, University of Regensburg, Germany.ORCID 0000-0002-7066-510X
Andreas ReissmannDepartment of Psychiatry and Psychotherapy, University of Regensburg, Germany.ORCID 0000-0003-3606-1000
Wolfgang StrubeFaculty of Medicine, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Augsburg, Bavaria, Germany.ORCID 0000-0003-2380-7651

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleTranscranial magnetic stimulation (TMS) is a well-established, noninvasive method for modulating cortical activity and has demonstrated efficacy in the treatment of depression. This study investigated potential interaction effects between antipsychotic augmentation and TMS efficacy using clinical records from two independent sites. In addition, exploratory analyses examined the association between resting motor threshold (RMT) and treatment outcomes.

methodsWe analyzed naturalistic data from patients with depressive symptoms treated at the TMS outpatient departments in Augsburg (

resultsAt the Augsburg site, 2 weeks after treatment initiation, patients not receiving antipsychotic augmentation exhibited significantly greater improvement in depressive symptom severity. However, differences between groups were not significant at treatment initiation or upon completion. Further, RMT analysis at Augsburg indicated a numerical but nonsignificant correlation with treatment outcome. At the Regensburg site, no consistent interaction effects were observed, and RMT analyses revealed nonsignificant correlations.

conclusionsTaken together, these findings suggest that TMS can remain effective in patients receiving concomitant antipsychotic augmentation alongside antidepressant and TMS treatment. Future research could usefully examine whether TMS remains effective in patients receiving different kinds of antipsychotic medication.

Indexed as

Antipsychotic AgentsDepressionMajor Depressive DisorderTranscranial Magnetic StimulationAdultAgedCombined Modality TherapyFemaleHumansMaleMiddle AgedPsychiatric Status Rating ScalesSeverity of Illness IndexTreatment OutcomeAntipsychotic Agentsantipsychotic augmentationdepression treatmentnoninvasive brain stimulationtheta burst stimulationtranscranial magnetic stimulation

Identifiers

PMID41728831
PMCPMC13283503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.